NYSE:PKI
USD
120.58
-1.73 (-1.41%)
PERKINELMER, INC.
Industry: Diagnostics & Research
End of Day: 26 September 2022 GMT-4
USD 120.58
-1.730 (-1.41%)
End of Day: 26 September 2022 GMT-4
Industry: Diagnostics & Research

Quote

Market Cap
15.220b
1M Daily Avg. Vol
743.540k
3Y P/B Range
2.15 - 4.47
52W Range
120.12 - 203.16
3Y P/S Range
2.66 - 5.01
3Y DivYield Range
0.139 - 0.395

Company Info

more

PerkinElmer provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segmen...

Key Ratios

more

3Y Rev Growth
21.46%
3Y Operating Profit Growth
43.81%
Operating Margin
20.76%
FCF Margin
18.17%
ROE
9.08%
ROA
4.59%

Income

more

Total Revenues (USD, MM)
5.02k
Net Income (USD, MM)
674.10
Net Margin
14.27%

Balance Sheet

more

Total Assets (USD, MM)
14.19k
Total Liabilities (USD, MM)
7.02k
Book Value Per Share
56.78

Cash Flow

more

Operations (USD, MM)
1.03k
Investing (USD, MM)
-3.45k
Financing (USD, MM)
2.10k

Details

Overview Company Info Key Ratios Income Balance Sheet Cash Flow

PerkinElmer's T-Cell Select reagent kit gets FDA approval for automation of T-SPOT.TB test

Trending News

PerkinElmer's T-Cell Select reagent kit has been approved by the US Food and Drug Administration for use in automating the company's T-SPOT.TB test workflow. The kit is designed to reduce hands-on time for laboratory personnel and lower overall costs. In a press release, the...

more

PerkinElmer gets FDA approval for T-Cell Select kit to automate TB test

  • PerkinElmer's (NYSE:PKI) Oxford Immunotec said that the U.S. Food and Drug Administration (FDA) approved the use of T-Cell Select reagent kit for automation of its T-SPOT.TB test workflow.
  • The T-Cell Select reagent kit...

more

PerkinElmer, Inc. (PKI) Presents at Baird's 2022 Global Healthcare Conference (Transcript)

PerkinElmer, Inc. (PKI)

Baird’s 2022 Global Healthcare Conference

September 13, 2022 10:50 AM ET

Company Participants

Prahlad Singh - CEO

Conference Call Participants

Tom Peterson -...

more

PerkinElmer: Focusing, Appealing

Towards the end of February, I concluded that there was a solid diagnosis for PerkinElmer (PKI) as it has seen a real boom following the pandemic. The company has seen strong "organic" performance, as I saw no reason to alter that stance.

Some...

more

PerkinElmer downgraded to hold at Stifel on CFO departure

  • Stifel has downgraded PerkinElmer (NYSE:PKI) from buy to hold following the recent announcement that Jamey Mock is leaving as the company's CFO.
  • The firm also reduced its price target to $170 from $190 (~13% upside...

more

PerkinElmer names new CFO as Jamey Mock joins Moderna

  • PerkinElmer (NYSE:PKI) announced Wednesday the departure of senior vice president and chief financial officer Jamey Mock as he joins Moderna (MRNA) as its finance chief.
  • The Board of healthcare diagnostics company,...

more

PerkinElmer, Inc. (PKI) CEO Prahlad Singh on Q2 2022 Results - Earnings Call Transcript

PerkinElmer, Inc. (PKI)

Q2 2022 Earnings Conference Call

August 04, 2022, 08:00 ET

Company Participants

Stephen Willoughby - VP, IR

Prahlad Singh - CEO, President & Director

James Mock - SVP & CFO

Conference...

more

PerkinElmer, Inc. 2022 Q2 - Results - Earnings Call Presentation

The following slide deck was published by PerkinElmer, Inc. in conjunction with their 2022 Q2 earnings call.

...

- SA Transcripts

https://seekingalpha.com/article/4529698-perkinelmer-inc-2022-q2-results-...

$NYSE:PKI

PerkinElmer Q2 2022 Earnings Preview

  • PerkinElmer (NYSE:PKI) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open.
more

PerkinElmer retraces gains as BofA downgrades citing valuation

  • Following an earnings-led rally yesterday, the shares of life sciences company PerkinElmer, Inc. (NYSE:PKI) traded lower in the morning hours Tuesday after Bank of America downgraded the stock to Neutral from Buy, citing...

more

All statements, views or opinions expressed here are the personal views of our users. They do not represent nor should they be construed as representing our statements, views or opinions. For the avoidance of doubt, any such statements, views or opinions are not and shall not be construed as financial advice.

Investing Made Smarter, Faster, Easier for Everyone